U.S. Machinery Stock News

What is driving sentiment around Telephone and Data Systems stock? Telephone and Data Systems (TDS) is under pressure after an earnings update coincided with heavy fiber investment, uncertainty following the wireless business sale, insider selling reports, a class action deadline, and technical downgrades. See our latest analysis for Telephone and Data Systems. The recent earnings disappointment and concerns around fiber spending, insider activity, and legal overhang come after a 10.89% year...

Some investors may be wondering if Napco Security Technologies at around US$41 is still offering value after its strong run, or if most of the opportunity is already priced in. The stock has seen mixed short term moves, with an 8.7% decline over the last week and a 2.5% gain over the last month. The 1 year return sits at 67.9% and the 5 year return at 165.9%. Recent coverage has focused on Napco Security Technologies as investors reassess growth expectations and risk after these share price...

Investors may be wondering if TKO Group Holdings at around US$190 a share is still priced attractively, or if most of the easy upside has already been captured. The stock closed at US$190.47, with a 3.7% gain over the last 7 days, a 3.3% decline over 30 days, an 8.0% decline year to date, and a 13.8% return over the last year, so the recent moves give a mixed picture of momentum and risk. Those swings sit against a longer track record where 3 year returns are 91.6% and 5 year returns are...

ITT (ITT) opened 2026 with Q1 revenue of US$1.2 billion and basic EPS of US$0.89, setting the tone for how the year could unfold against its recent track record. The company has seen quarterly revenue move from US$913 million in Q1 2025 to US$1.2 billion in Q1 2026, while basic EPS ranged from US$1.33 in Q1 2025 to US$1.65 in Q4 2025 before the latest Q1 print. This puts the focus firmly on how much of this top line is flowing through to margins. See our full analysis for ITT. With the latest...

United Therapeutics (UTHR) opened 2026 with Q1 revenue of US$781.5 million and basic EPS of US$6.32, alongside trailing twelve month revenue of US$3.2 billion and EPS of US$29.29. These figures place the latest quarter within a broader earnings run. Over recent periods, revenue has moved from US$735.9 million in Q4 2024 to the current US$781.5 million. Basic EPS has ranged between US$6.32 and US$8.41 across the last five quarters, giving investors a clearer view of profit per share as margins...

If you are wondering whether Zoetis at around US$111 is a bargain or a value trap, this article will explain what the current price might be implying about the stock. The stock has recently retreated, with returns of 2.3% over 7 days, 6.0% over 30 days, 11.7% year to date, and 27.6% over 1 year. This may have shifted how the market views its risk and reward trade off. Recent coverage has focused on Zoetis as a major animal health company, highlighting how the sector can be influenced by...

Hasbro has signed a long term lease for new creative office space at The Lot at Formosa in West Hollywood. The move expands Hasbro's presence at a historic Hollywood studio campus in the core of the entertainment production district. The new space is intended to support the company’s growing focus on branded entertainment and content related activities. For investors watching NasdaqGS:HAS, the new lease lands at a time when the stock trades at $97.48, with returns of 3.7% over the past...

Morgan Stanley (NYSE:MS) has been admitted as the first international Remote Trading Member of the Abu Dhabi Securities Exchange (ADX). The move gives the firm and its global clients direct market access to securities listed on ADX. This admission marks an expansion of Morgan Stanley's trading footprint into the United Arab Emirates capital markets. Morgan Stanley operates as a global financial services company with businesses across investment banking, trading, wealth management, and asset...

Revolution Medicines (NasdaqGS:RVMD) sent a cease and desist letter to Erasca, alleging patent infringement and trade secret misappropriation around RAS inhibitor programs. The company advanced daraxonrasib’s regulatory path and released new Phase 3 data, ahead of a high profile ASCO Plenary Presentation. The combination of legal action and clinical progress raises fresh questions about future market exclusivity, licensing potential, and competitive positioning in RAS targeted...

Coupang (CPNG) opened Q1 2026 with revenue of about US$8.5b and a basic EPS loss of US$0.15, alongside a trailing twelve month basic EPS loss of US$0.09 on revenue of roughly US$35.1b. This keeps the focus firmly on how efficiently that scale is translating into earnings. Over recent quarters the company has seen revenue move from about US$7.9b in Q1 2025 to US$9.3b in Q3 2025 before landing at US$8.5b this quarter. Over the same period, quarterly basic EPS has swung from a profit of US$0.06...

Wolfspeed recently reported fiscal third-quarter 2026 results showing sales of US$150.2 million and a net loss of US$119.9 million, while also refinancing debt by raising about US$475.9 million and redeeming its Senior Secured Notes due 2030. Alongside strengthening its balance sheet, the company is pivoting its silicon carbide business toward AI data centers and industrial applications, supported by new high-voltage product launches and leadership additions to oversee legal, compliance, and...

Merck (NYSE:MRK) has closed its acquisition of Terns Pharmaceuticals, adding TERN-701, a chronic myeloid leukemia drug with FDA Breakthrough Therapy Designation, to its oncology pipeline. The company has also published new research on biocatalytic synthesis for enlicitide decanoate, a first in class oral PCSK9 inhibitor candidate for cholesterol management. Merck, trading at $113.56, has a 1 year return of 48.7% and a 5 year return of 78.7%, with year to date performance of 6.7%. Against...

In late April 2026, Meta Platforms completed a series of US$25.00 billion senior unsecured bond issues across multiple maturities while also reporting first‑quarter revenue of US$56.31 billion and net income of US$26.77 billion, supported by AI‑enhanced advertising performance. At the same time, Meta sharply raised its 2026 capital expenditure guidance into the roughly US$125.00–US$145.00 billion range to fund AI infrastructure and large data center projects such as the planned...

Arbor Realty Trust recently reported quarterly results after previously beating expectations despite a year-on-year revenue decline, while analysts still project further pressure on earnings and revenue. Analyst views remain mixed, with some emphasizing earnings estimate cuts and non-performing loan work-outs, while others still highlight operational progress and capital redeployment efforts. Next, we’ll examine how this mixed analyst backdrop ahead of Arbor Realty Trust’s earnings update...

Lear Corporation (NYSE:LEA) reports stronger-than-expected international revenue, with outperformance in Europe, Africa, and South America. The company announces expanded business with major automakers, including General Motors and Audi. Lear highlights accelerated growth with Chinese automakers, pointing to a changing geographic revenue mix. Lear, a global supplier of automotive seating and electrical systems, sits at the center of key shifts in the auto industry as customers invest in new...

Core Scientific (NasdaqGS:CORZ) has agreed to acquire Polaris DS LLC as part of a plan to expand its Muskogee, Oklahoma data center campus. The Muskogee project is aimed at adding power capacity focused on high-density colocation and AI oriented workloads. This move reflects a greater focus on AI and high-performance computing infrastructure alongside Core Scientific's existing Bitcoin mining operations. Core Scientific, trading at $24.63, has delivered a 25.9% return over the past week and...

Aurinia Pharmaceuticals Inc. has reported its first-quarter 2026 results, with revenue rising to US$77.71 million and net income to US$34.36 million, lifting diluted earnings per share from continuing operations to US$0.25 compared with US$0.16 a year earlier. The quarter underscored the growing commercial role of LUPKYNIS in lupus nephritis, as higher sales and improved gross margins helped Aurinia deliver stronger profitability while reaffirming its 2026 revenue guidance. Next, we’ll...

Considering whether Medtronic stock is starting to look like value, or if the recent share price still leaves limited upside for new buyers. Medtronic closed at US$77.60, with recent total returns showing a 2.2% loss over 7 days, a 10.1% loss over 30 days, and a 19.2% loss year to date, adding to a 3.7% loss over 1 year, 4.3% loss over 3 years, and 26.6% loss over 5 years. Recent coverage has continued to focus on Medtronic as a major global medical technology company, highlighting how it is...

Phoenix Asia Holdings (PHOE) has drawn fresh attention after recent trading, with the stock last closing at $28.60. Investors are weighing its substructure construction focus in Hong Kong against recent short term share price moves. See our latest analysis for Phoenix Asia Holdings. The recent 1 day share price return of 39.14% decline contrasts sharply with the 7 day share price return of 83.92% and the year to date share price return of 76.11%. The 1 year total shareholder return is very...

How Goldman Sachs Group (GS) Is Positioned After Recent Performance Goldman Sachs Group (GS) has drawn fresh attention after recent share price gains, with the stock up 2.0% over the past day, 3.5% over the past week and 8.2% over the past month. That move comes alongside a 5.3% total return over the past 3 months and 73.4% over the past year, putting the current share price at $937.35 and raising questions about how the company’s fundamentals line up with recent returns. See our latest...

First Mid Bancshares recently reported first-quarter 2026 results showing higher net interest income of US$70.79 million and net income of US$26.33 million compared with a year earlier, while also announcing ongoing leadership succession, a regular US$0.25 dividend, and completion of a modest share repurchase program. An interesting angle for investors is that incoming CEO Matthew K. Smith, a long-time finance leader and former CFO, will combine board, risk committee, and executive...

Investors may be wondering if Soleno Therapeutics at around US$52.94 is priced attractively after its past swings, or if most of the opportunity is already reflected in the stock. The share price shows a mixed picture, with returns of 0.3% over 7 days, 1.3% over 30 days, 12.2% year to date, a 29.1% decline over the last year, and a very large gain over 3 years that is more than 10x. Recent headlines around Soleno Therapeutics have focused on its progress as a clinical stage biopharmaceutical...

Context for Mattel after a weak three month stretch Mattel (MAT) has drawn fresh attention after a weak past 3 months for the stock, with a negative 28.6% total return, in contrast with modest gains over the past month and week. See our latest analysis for Mattel. At a share price of $15.08, Mattel’s short-term momentum has increased with a 1 month share price return of 3.93%, but the 1 year total shareholder return of 13.48% still indicates weaker longer-term performance. If you are...

Kimco Realty (KIM) is back on investors’ radar after Q1 2026 results, a guidance update, and dividend news put a fresh spotlight on the real estate investment trust’s earnings power and income profile. See our latest analysis for Kimco Realty. At a share price of $23.80, Kimco Realty has seen a 5.97% 1 month share price return and 18.64% year to date share price return. Its 1 year total shareholder return of 20.81% and 3 year total shareholder return of 51.72% suggest momentum has been...